CTLA4 and Familial prostate cancer: Ipilimumab, 1 type of monoclonal antibodies against human cytotoxic T-lymphocyte protein 4 (CTLA-4), showed an exciting therapeutic effect in melanoma, lung cancer, prostate cancer as a single dose or combination with other chemotherapy.[5–7]